Insider · CIK 0001789857
Jonathan Zalevsky
officer
Files at NKTR (NEKTAR THERAPEUTICS). First filing Nov 20, 2024, latest Nov 25, 2025.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 7
$0 bought, $217k sold
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
NKTR: NEKTAR THERAPEUTICS
NKTROct 9, 2026 · close 41.17
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 38Weak | NEKTAR THERAPEUTICS | $63k 1,157 shares | -6% | +721% from low-7% from high | |
| 10Weak | NEKTAR THERAPEUTICS | $58k 1,721 shares | -9% | +390% from low0% from high | |
| 10Weak | NEKTAR THERAPEUTICS | $15k 485 shares | -2% | +296% from low-3% from high | |
| 30Weak | NEKTAR THERAPEUTICS | $19k 725 shares | -4% | +264% from low-10% from high | |
| 30Weak | NEKTAR THERAPEUTICS | $7,177 10,712 shares | -3% | +43% from low-52% from high | |
| 42Moderate | NEKTAR THERAPEUTICS | $48k 51,115 shares | -14% | - | |
| 30Weak | NEKTAR THERAPEUTICS | $7,863 7,785 shares | -3% | - |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Dec 22, 2025 | NKTR NEKTAR THERAPEUTICS | AGrant or award Common Stock | +6,250 | $0.00 | $0 | 25,221 | Dec 23, 2025 |
| Dec 22, 2025 | NKTR NEKTAR THERAPEUTICS | AGrant or award Stock Optionderivative | +25,000 | $0.00 | $0 | 25,000 | Dec 23, 2025 |
| Nov 21, 2025 | NKTR NEKTAR THERAPEUTICS | AGrant or award Common Stock | +2,666 | $0.00 | $0 | 20,128 | Nov 25, 2025 |
| Nov 25, 2025 | NKTR NEKTAR THERAPEUTICS | SOpen-market sale Common Stock | -1,157 | $54.28 | $63k | 18,971 | Nov 25, 2025 |
| Nov 21, 2025 | NKTR NEKTAR THERAPEUTICS | AGrant or award Stock Optionderivative | +4,766 | $0.00 | $0 | 4,766 | Nov 25, 2025 |
| Sep 4, 2025 | NKTR NEKTAR THERAPEUTICS | SOpen-market sale Common Stock10b5-1 | -793 | $32.43 | $26k | 18,390 | Sep 8, 2025 |
| Sep 4, 2025 | NKTR NEKTAR THERAPEUTICS | SOpen-market sale Common Stock10b5-1 | -432 | $33.60 | $15k | 17,958 | Sep 8, 2025 |
| Sep 4, 2025 | NKTR NEKTAR THERAPEUTICS | SOpen-market sale Common Stock10b5-1 | -189 | $34.41 | $6,503 | 17,769 | Sep 8, 2025 |
| Sep 4, 2025 | NKTR NEKTAR THERAPEUTICS | SOpen-market sale Common Stock10b5-1 | -307 | $35.69 | $11k | 17,462 | Sep 8, 2025 |
| Sep 2, 2025 | NKTR NEKTAR THERAPEUTICS | SOpen-market sale Common Stock10b5-1 | -485 | $30.10 | $15k | 19,183 | Sep 4, 2025 |
| Aug 19, 2025 | NKTR NEKTAR THERAPEUTICS | SOpen-market sale Common Stock | -725 | $26.59 | $19k | 19,668 | Aug 21, 2025 |
| Aug 19, 2025 | NKTR NEKTAR THERAPEUTICS | AGrant or award Stock Optionderivative | +16,666 | $0.00 | $0 | 16,666 | Aug 21, 2025 |
| May 19, 2025 | NKTR NEKTAR THERAPEUTICS | SOpen-market sale Common Stock | -10,712 | $0.67 | $7,177 | 305,892 | May 21, 2025 |
| Dec 19, 2024 | NKTR NEKTAR THERAPEUTICS | SOpen-market sale Common Stock | -51,115 | $0.94 | $48k | 326,904 | Dec 20, 2024 |
| Dec 13, 2024 | NKTR NEKTAR THERAPEUTICS | AGrant or award Common Stock | +135,000 | $0.00 | $0 | 378,019 | Dec 17, 2024 |
| Dec 13, 2024 | NKTR NEKTAR THERAPEUTICS | AGrant or award Stock Optionderivative | +270,000 | $0.00 | $0 | 270,000 | Dec 17, 2024 |
| Dec 13, 2024 | NKTR NEKTAR THERAPEUTICS | AGrant or award Stock Optionderivative | +375,000 | $0.00 | $0 | 375,000 | Dec 17, 2024 |
| Nov 19, 2024 | NKTR NEKTAR THERAPEUTICS | SOpen-market sale Common Stock | -7,785 | $1.01 | $7,863 | 243,019 | Nov 20, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.